HanchorBio 2025 Milestones

Patient First, Data Driven.

HanchorBio is a clinical-stage biotechnology company advancing differentiated immuno-oncology biologics through its proprietary FBDB™ (Fc-Based Designer Biologics) platform. In 2025, the platform achieved meaningful validation across clinical development, global scientific recognition, intellectual property, and capital markets, marking its transition from platform build-out to clinical execution.

FBDB™ Platform Overview

The FBDB™ platform enables the rational design of multi-functional fusion proteins intended to address key limitations of existing immuno-oncology therapies. Platform strengths demonstrated in 2025:

Rational multi-target engagement to improve therapeutic index in solid tumors
A diversified pipeline spanning clinical and preclinical stages
Platform scalability validated through clinical data, global conferences, peer-reviewed publication, IP grants, and a completed licensing transaction

Key Milestones in 2025

Clinical & R&D Progress

HCB101 advanced into a Phase 1b/2 clinical trial
2L GC combo therapy demonstrated an 80% objective response rate (ORR), significantly outperforming historical standard-of-care (26.5%)
TFDA approvals obtained for HCB101 combination therapy (HNSCC, CRC)
HCB301 entered Phase I clinical trial and completed safety evaluations for two dose cohorts with favorable tolerability
HCB303 entered IND-enabling preparation stage
HCB206: Program expansion into auto-immune disease, broadening platform applicability beyond oncology

Global Scientific Presence

ASCO 2025: Presentation of preliminary clinical data for HCB101
ASH 2025: First-in-human monotherapy results of HCB101
ESMO Immuno-Oncology Congress: Selected for mini-oral presentation
Journal of Hematology & Oncology (JHO): Peer-reviewed publication (IF: 40.4)
SITC 2025: Preclinical data presentation for HCB301
CBA Annual Meeting: Invited participant; sole innovative drug company from Taiwan

Awards & Recognition

IMAPAC 2025 Taiwan Biopharma Excellence Award
Taiwan BIO Awards 2025 “Startup of the Year

Business & Corporate Progress

HCB101 licensing agreement executed
- USD 10 million upfront payment
- Up to USD192 million in development and commercial milestones
Company listed on the Taiwan Emerging Stock Market (7827.TPEx)
- Application submitted for listing on the Taiwan Innovation Board (TIB), pending approval
U.S. patent granted for HCB101

Key Leadership Appointment

Alvin Luk, PhD, MBA, CCRA, was appointed as Group President & Chief Medical Officer (CMO), strengthening clinical strategy, global development execution, and platform-to-patient translation

Summary

2025 marks HanchorBio’s evolution from platform establishment to clinical and commercial validation.
The FBDB™ platform has progressed beyond concept, demonstrating its ability to generate clinically relevant therapeutics supported by human data, regulatory momentum, and external partnerships.

HanchorBio enters 2026 as a company with:

Multiple clinical-stage assets
A validated biologics platform
Growing global visibility
Clear pathways toward value inflection